secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001104659-25-062162
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics stockholders approve doubling authorized common stock to 100M shares
--------------------------------------------------------------------------------

- Stockholders approved amendment to increase authorized common shares from 50M to 100M.
- All eight director nominees elected; Ernst & Young AG ratified as auditor for FY2025.
- Vote results: 16.3M for share increase, 2.2M against, 12k abstain; 18.0M ratified auditor.
- Adjournment proposal also approved to allow further proxy solicitation if needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925062162/0001104659-25-062162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925062162/tm2518700d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-062162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer